Changes in elderly women's health-related quality of life following discontinuation of hormone replacement therapy by Heller, Debra A et al.
BioMed  Central
Page 1 of 15
(page number not for citation purposes)
BMC Women's Health
Open Access Research article
Changes in elderly women's health-related quality of life following 
discontinuation of hormone replacement therapy
Debra A Heller*1,2,  C a r o lHG o l d 2, Frank M Ahern2, Kristine E Pringle1, 
Theresa V Brown3 and Margaret R Glessner1
Address: 1First Health Services/The PACE Program, 4000 Crums Mill Road, Suite 301, Harrisburg, PA 17112 USA, 2Department of Biobehavioral 
Health, The Pennsylvania State University, 315 East Health and Human Development, University Park, PA 16802 USA and 3Pennsylvania 
Department of Aging/The PACE Program, 555 Walnut Street, 5th Floor, Harrisburg, PA 17101 USA
Email: Debra A Heller* - daheller@fhsc.com; Carol H Gold - gum@psu.edu; Frank M Ahern - f4a@psu.edu; 
Kristine E Pringle - pringlkr@fhsc.com; Theresa V Brown - tbrown@state.pa.us; Margaret R Glessner - pglessner@fhsc.com
* Corresponding author    
Abstract
Background: Many women have discontinued hormone replacement therapy (HRT) in view of recent
findings. The goal of this study was to determine if HRT discontinuation is associated with changes in
health-related quality of life (HRQOL) in elderly women.
Methods: We studied women enrolled in Pennsylvania's Pharmaceutical Assistance Contract for the
Elderly (PACE) program, linking prescription claims with data from a longitudinal mail survey. HRQOL
measures included the number of days out of the last 30 that physical health was not good and analogous
measures for mental health, pain, and interference with activities, as well as a composite "healthy days"
measure developed by CDC. Longitudinal analyses focused on 2,357 women who completed surveys in
both 2002 and 2003, and who used HRT at baseline (mean age = 75.5, range = 65–102). Propensity scores
were used to match HRT continuers and discontinuers according to HRT type, demographics, and baseline
HRQOL. Analysis of covariance was used to compare HRQOL change in continuers and discontinuers.
Results: Between 2002 and 2003, 43% of HRT users discontinued therapy. Analysis of covariance to
examine HRQOL change revealed complex interactions with age. Discontinuers aged 65–74 reported
greater increases in days in which mental health was not good (p < .05), fewer "healthy days" (p < .05),
more days in which health interfered with activities (p < .01), and more days with pain (p < .01). Among
women aged 75–84, HRT discontinuers reported more days in which physical health was not good (p <
.01); no other significant effects were observed in this group. Relative to HRT continuers, discontinuers
aged 85 and older experienced apparent HRQOL improvements following cessation, with fewer days in
which physical health was not good (p < .01), fewer days of poor mental health (p < .05), and more "healthy
days" (p < .01).
Conclusions:  These results suggest that there are substantial age differences in response to HRT
discontinuation. While women aged 65–74 experienced apparent declines in HRQOL following HRT
cessation, women aged 85 and older experienced relative improvements. The HRQOL declines observed
among younger women underscore the importance of communication between clinicians and patients
throughout the discontinuation process. These results also demonstrate the value of HRQOL surveillance
as a component of health program administration.
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Background
Few health topics are currently associated with as much
confusion as the issue of hormone replacement therapy
(HRT) for postmenopausal women. Historically, the
results of observational studies spanning several decades
have suggested that HRT confers important cardiovascular
benefits for postmenopausal women [1,2]. In July of
2002, however, the combination HRT component of the
Women's Health Initiative (WHI) study-a randomized
placebo-controlled trial-was halted due to an excess inci-
dence of coronary events, stroke, pulmonary embolism,
and breast cancer among women receiving estrogen and
progestin in combination [3,4]. In February of 2004, the
estrogen-only arm of the WHI study was similarly halted
due to observed increases in the risk of stroke among
women with prior hysterectomy who received unopposed
estrogen [5].
The well-publicized halting of the WHI combination ther-
apy trial, along with emerging evidence from other stud-
ies, sparked intense debate and ultimately led to an
important paradigm shift with respect to HRT. Guidelines
such as those released in 2002 by the U.S. Preventive Serv-
ices Task Force stress that the harmful effects of HRT
related to breast cancer and cardiovascular risk outweigh
potential benefits such as increased bone density, and that
HRT should therefore not be used for the prevention of
chronic conditions in postmenopausal women [6]. The
newer guidelines and warnings are in sharp contrast to
HRT's cultural history and early marketing, which por-
trayed hormone replacement as fundamental for the pres-
ervation of health, youth, and femininity. Many older
women who are now long past menopause initiated HRT
decades ago with the belief that they would continue with
the therapy for life. The recent shifts in guidelines and
practice have therefore presented a dilemma for clinicians
and patients, and many women have opted to discontinue
HRT [7].
Enhanced quality of life is a frequently-cited benefit of
HRT [8], but recent studies addressing quality of life have
produced mixed results. A number of observational stud-
ies comparing HRT users and non-users have observed
better psychological health and health-related quality of
life among HRT users [9-11]. Recent randomized clinical
trials, however, have reported fewer apparent benefits for
postmenopausal women. For example, comparing HRT
users and non-users in the Heart and Estrogen/Progestin
Replacement Study (HERS), Hlatky and his colleagues
found no evidence of a general benefit in quality of life
associated with HRT [12]. Among women with menopau-
sal symptoms such as flushing, however, HRT use pro-
duced improvements in mental health and depressive
symptoms. Similar findings were reported by Hays et al.
using WHI data [13]. Both the WHI and HERS studies
concluded that, aside from women experiencing acute
menopausal symptoms, HRT users did not differ from
non-users with respect to quality of life. No published
studies to date, however, have specifically examined the
impact of HRT discontinuation on quality of life. In addi-
tion, relatively few HRT studies have focused explicitly on
elderly women, but have instead focused on younger
postmenopausal women, who are most likely to experi-
ence acute menopausal symptoms. Elderly women com-
prise an important segment of the population of HRT
users, and more research on elderly HRT users is needed.
It is important for clinicians to understand the potential
changes in quality of life that may be associated HRT dis-
continuation, and how women of different ages may
respond to HRT discontinuation.
The goal of this study was to determine if HRT discontin-
uation is associated with changes in health-related quality
of life in a population of elderly women. We studied
women enrolled in a state pharmaceutical assistance pro-
gram for the elderly, linking prescription claims with data
from a longitudinal mail survey that addressed health-
related quality of life. The availability of longitudinal sur-
vey data for HRT continuers and discontinuers provides
an important opportunity to examine the impact of HRT
discontinuation on the quality of life of elderly women.
Methods
Study population
Subjects included women who were enrolled during 2002
and 2003 in Pennsylvania's Pharmaceutical Assistance
Contract for the Elderly (PACE), a state program provid-
ing prescription drug assistance to elderly with low to
moderate incomes. All PACE applicants complete a
detailed application form prior to enrollment. Depending
on their income, enrollees are then required to re-enroll
either annually or biannually. For purposes of research
and evaluation, PACE includes an optional two-page sur-
vey – the Survey on Health and Well-Being – with all new
and renewal enrollment applications. The survey was
approved by the Institutional Review Board of the Penn-
sylvania State University. Historical data suggest that most
PACE cardholders view the survey positively, with annual
response rates exceeding 70% [14].
In order to examine longitudinal associations, the present
study focuses on women who completed both the 2002
and 2003 Surveys on Health and Well-Being, and who
were HRT users at baseline (i.e., the time that they com-
pleted the 2002 survey) based on prescription claims
review.
Measurement of health-related quality of life
Health related quality of life (HRQOL), although vari-
ously defined, refers generally to those aspects of qualityBMC Women's Health 2005, 5:7 http://www.biomedcentral.com/1472-6874/5/7
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of life that are clearly related to either physical or mental
health [15,16]. The U.S. Centers for Disease Control and
Prevention (CDC) has described HRQOL as "an individ-
ual's or group's perceived physical and mental health over
time" [15]. Over the last three decades, HRQOL has been
increasingly recognized as an important component of
health status that should be considered when evaluating
the effectiveness of health programs and medical treat-
ments [17].
The PACE Survey on Health and Well-Being includes a
series of HRQOL questions that were adapted from the
CDC's Behavioral Risk Factor Surveillance System
(BRFSS) telephone survey. The BRFSS HRQOL measures
include a core set of four questions as well as an optional
set of questions related to pain perception and activity
limitation [15]. Moderate to excellent retest reliabilities
for the HRQOL module questions have been reported
[18]. Although brief, the BRFSS HRQOL module has pro-
duced results comparable to the SF-36 in prior studies,
and has successfully distinguished groups varying in clin-
ical diagnoses [19,20]. Recent research has also demon-
strated that the instrument is responsive to changes in
health status and is well-accepted by older adults [21,22].
Table 1 displays the BRFSS HRQOL questions included in
the PACE survey. The present analysis focuses on the
number of days out of the last 30 that physical health was
not good and analogous measures for mental health,
interference of health with activities, and pain. The
present study also utilized composite measures of
"unhealthy days" and "healthy days" developed by CDC.
The total number of unhealthy days in the last month was
estimated by summing the number of "not good" physical
and mental days, with a logical maximum of 30 days.
CDC's measure of healthy days, a positive complementary
form of unhealthy days, was computed by subtracting the
number of unhealthy days from 30 [15,23]. Prior studies
have demonstrated that the healthy and unhealthy days
composite variables are valid and responsive measures of
perceived health [15,19].
Measurement of HRT and other prescription drug use
PACE utilizes a point-of-sale claim payment system; at the
time of dispensing, pharmacies submit electronic claims
to PACE for adjudication and reimbursement. Complete
data on all prescription medications obtained by study
participants were therefore available for study, provided
that participants filled the prescriptions by using their
PACE cards. All HRT prescriptions, and details regarding
the specific type of HRT, were identified by linking claim
records for study participants to a database of drug
attributes (Red Book®) provided by Medical Economics/
Thomson Healthcare (Montvale, New Jersey). Systemic
forms of HRT, including oral and transdermal products,
were distinguished from topical forms on the basis of each
dispensed product's formulation code.
HRT status was evaluated by identifying all systemic HRT
claims dispensed between October 1, 2001 and March 31,
2004. PACE allows only a 30-day supply of medication to
be dispensed per prescription refill. In order to allow for
early refills and potential prescription overlap, baseline
HRT users were defined as individuals who filled one or
more HRT prescriptions during the 45 days preceding
their 2002 baseline survey response date. For follow-up
Table 1: Health-related quality of life questions included in survey
Core HRQOL module questions
1. Would you say that in general your health is: excellent, very good, good, fair or poor?
2. Now thinking about your physical health, which includes physical illness and injury, for how many days during the past 30 days was your 
physical health not good?
3. Now thinking about your mental health, which includes stress, depression, and problems with emotions, for how many days during the past 
30 days was your mental health not good?
4. During the past 30 days, for about how many days did poor physical or mental health keep you from doing your usual activities, such as self-
care, work, or recreation?
Optional HRQOL module questions (pain and activity limitation)
1. During the past 30 days, for about how many days did PAIN make it hard for you to do your usual activities, such as self-care, work, or 
recreation?
2. Are you limited in any activities because of any impairment or health problem?
3. What is the MAJOR impairment or health problem that limits your activities?
4. For HOW LONG have your activities been limited because of your impairment or health problem? Please give the length of time.
5. Because of any impairment or health problem, do you need the help of other persons with your PERSONAL CARE needs, such as eating, 
bathing, dressing, or getting around the house?
6. Because of any impairment or health problem, do you need the help of other persons in handling your ROUTINE needs, such as everyday 
household chores, doing necessary business, shopping, or getting around for other purposes?BMC Women's Health 2005, 5:7 http://www.biomedcentral.com/1472-6874/5/7
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status evaluation, claims were examined for the entire
time interval between the baseline survey date and up to
90 days after the 2003 follow-up survey date. Discontinu-
ers were defined as individuals whose last HRT prescrip-
tion was filled more than 45 days prior to their follow-up
survey response date. Women who filled one or more HRT
prescriptions during the 45 days immediately preceding
the follow-up survey date were identified as continuers. A
small number of baseline HRT users (n = 143) who did
not have any HRT claims during the 45 days prior to the
follow-up survey, but who filled HRT prescriptions within
90 days after their 2003 survey date, were also categorized
as continuers. Baseline and follow-up HRT use for each
study participant was further categorized as either unop-
posed estrogen (estrogen without progestin) or combina-
tion therapy (estrogen with progestin).
Statistical analyses
Descriptive statistics
All statistical analyses were conducted using the Statistical
Analysis System (SAS) for Windows, Version 8.2 (SAS
Institute, Cary, NC). Descriptive statistics were used to
describe HRT continuers and discontinuers in terms of
demographic characteristics, self-reported health behav-
iors, HRT and other drug utilization, and HRQOL survey
measures.
Propensity scores
The goal of the present study was to compare HRQOL
change in HRT continuers and discontinuers. A limita-
tion, however, is that women who choose to continue
HRT may differ fundamentally from women who discon-
tinue HRT. If so, then these fundamental differences may
also be reflected in differential change in HRQOL, leading
to biased estimates of the effect of HRT discontinuation
on HRQOL. Such bias is inherent in many observational
studies, in contrast to randomized trials in which subjects
are assigned randomly to treatment or non-treatment
groups.
Propensity scores have been proposed as a methodologi-
cal strategy for bias control in observational studies [24-
26]. The propensity score is defined as the conditional
probability that an individual is a member of a treatment
group, given all available covariate values [26]. Compared
to traditional stratification, matching, or covariate adjust-
ment methods, propensity scores offer the advantage of
reducing a large number of background covariates to a
single scalar value. Once propensity scores have been cre-
ated, traditional procedures such as stratification or
matching can then be applied to the propensity scores
[26].
In the context of the present study, the propensity score
represents the conditional probability (ranging from 0 to
1) that a woman using HRT at baseline will discontinue
HRT, given her baseline characteristics. Propensity scores
were created through a multivariate logistic regression
analysis to predict the binary outcome of HRT discontin-
uation at the time of the follow-up (2003) survey, based
on multiple explanatory variables measured at baseline
(2002). The baseline explanatory variables included
demographic measures (age, race, income, marital status,
education, long-term care residence, and urban/rural resi-
dence), self-reported health behaviors (alcohol use and
smoking), type of HRT, and non-drug utilization.
Matching of continuers and discontinuers
Continuers and discontinuers were matched using a SAS
macro provided by researchers at the Mayo Clinic Divi-
sion of Biostatistics [27]. The propensity score generated
in the multivariate logistic regression described above was
used as the primary matching factor. To control further for
potential baseline differences in HRQOL, the baseline
HRQOL measures were also subjected to principal com-
ponents analysis, a data reduction technique that summa-
rizes the variance shared by a set of variables [28,29]. The
first principal component, which accounted for 71.9% of
the total variance in the baseline HRQOL measures, was
then used as a secondary matching variable. The rationale
for including the principal component score in the match-
ing algorithm was to ensure that the matched samples of
continuers and discontinuers were well-balanced in terms
of all baseline HRQOL measures. In addition to the pro-
pensity and baseline HRQOL principal component
scores, continuers and discontinuers were further
matched by baseline HRT type (estrogen alone or combi-
nation) and age group (65–74 years, 75–84 years, and 85
or older). Using the above-described selection factors, a
single best-matching HRT continuer was identified for
each HRT discontinuer. All subsequent analyses were con-
ducted using the reduced sample of matched HRT contin-
uers and discontinuers.
Analysis of covariance (ANCOVA)
Once the final matched sample of continuers and discon-
tinuers was created, analysis of covariance (ANCOVA) was
used to examine the impact of HRT continuation or dis-
continuation on HRQOL change. As discussed by Vickers
and Altman [30], ANCOVA may be used to compare
change in one or more groups by predicting follow-up
scores from baseline scores and a treatment group indica-
tor. In the present study, the ANCOVA model equation
may be visualized as:
HRQOL2= Constant + β 1·HRQOL1+ β 2·HRT Group
where HRQOL1 and HRQOL2 are baseline and follow-up
HRQOL scores, β 1 and β 2 are coefficients to be estimated,
and HRT Group is a binary variable coded 1 for HRT dis-BMC Women's Health 2005, 5:7 http://www.biomedcentral.com/1472-6874/5/7
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continuation and 0 for HRT continuation. Using the SAS
GLM procedure, separate ANCOVA analyses were per-
formed for each of the HRQOL questions. To explore age
differences in response to HRT discontinuation, separate
analyses were conducted within three age groups: 65–74
years, 75–84 years, and 85 years or older.
Results
A total of 4,236 women completed a survey in 2002 and
used HRT at baseline, based on one or more claims for
systemic HRT products during the 45 days preceding their
2002 survey return date. Of these women, 1,076 (25.4%)
had incomes low enough to qualify them for two years of
PACE coverage rather than only one year, and were there-
fore not required to reapply for coverage in 2003. Among
the remaining 3,160 women, 2,899 reapplied for PACE
coverage in 2003, and 2,357 of those reapplying also com-
pleted the follow-up survey in 2003. The mean interval
between the baseline and follow-up surveys was 367 days.
Of the 2,357 baseline HRT users who completed surveys
in both 2002 and 2003, 1,015 women (43.1%) discontin-
ued HRT between the time of their baseline and follow-up
surveys.
Determinants of HRT discontinuation
Table 2 summarizes the results of a multivariate logistic
regression analysis to predict HRT discontinuation from
multiple baseline measures, including demographic fac-
tors, self-reported health behaviors, type of HRT, non-
HRT prescription drug use, and baseline HRQOL. Percent-
age frequencies for each categorical measure and means
for each continuous measure are shown for HRT continu-
ers and discontinuers. Table 2 also presents the parameter
estimates, standard errors, adjusted odds ratios with asso-
ciated confidence limits, and probability values for all
independent variables. The strongest predictor of HRT dis-
continuation was type of HRT used at baseline, with com-
bination users being three times as likely as unopposed
estrogen users to discontinue HRT (O.R. = 3.03, p <
.0001). This result is not surprising given the fact that ini-
tial media attention focused on the WHI combination
therapy arm that was halted in 2002; the unopposed
estrogen arm of the WHI study was not halted until 2004.
On average, HRT discontinuers had higher annual
incomes than HRT continuers ($13,999 vs. $13,805, O.R.
per $1,000 = 1.06, p = .0283). Relative to women living in
urban areas, women residing in rural or semi-rural areas
appeared more likely to discontinue HRT, although this
result did not achieve conventional significance (O.R. =
1.17, p = .0948). Women who had any baseline use of car-
diovascular drugs were significantly more likely than non-
users to discontinue HRT (O.R. = 1.25, p = .0471), as were
women who had any baseline use of medications used to
treat osteoporosis (O.R. = 1.36, p = .0146). The total
number of non-HRT medication classes used during the
45 days preceding the baseline survey was also signifi-
cantly associated with discontinuation – women who
used higher numbers of medications were less likely to
discontinue HRT (O.R. for each additional therapeutic
class = 0.95, p = .0021).
Impact of discontinuation on HRQOL
As discussed above, HRT continuers and discontinuers
were matched on the basis of the following factors: 1) the
propensity scores obtained from the multivariate logistic
regression, 2) the first principal component scores for the
combined baseline HRQOL measures, 3) age group, and
4) type of HRT used at baseline. Of the 2,357 women
present in the original sample, 1,770 respondents
(75.1%) were successfully matched using these criteria.
The final matched sample included 65.4% of the original
sample of HRT continuers, and 86.5% of the original sam-
ple of discontinuers. Relaxing the matching algorithm
requirements would have resulted in a higher number of
matched subjects, but would have provided less control
for selection bias.
Table 3 summarizes the results of analysis of covariance to
examine associations between HRT discontinuation and
changes in HRQOL. For each of the follow-up HRQOL
measures, mean values for HRT continuers and discontin-
uers are shown for three groups: 65–74 years, 75–84
years, and 85 years or older. Each ANCOVA model pre-
dicted follow-up HRQOL score from the corresponding
baseline HRQOL measure and HRT group. Ancillary
information to accompany the ANCOVA results in Table
3 is shown in Figures 1 through 5, which present the
adjusted mean change in HRQOL for each measure by age
group, while controlling for baseline HRQOL scores.
Striking age differences are apparent in the associations
between HRT group and follow-up HRQOL, controlling
for baseline HRQOL. Within the youngest group of
women – aged 65–74 – HRT discontinuation was associ-
ated with a significant increase in the days in which men-
tal health was not good (adjusted mean change = 1.1 days,
p = .0329), fewer healthy days (adjusted mean change = -
1.5 days, p = .0400), more days in which physical or
mental health interfered with activities (adjusted mean
change = 1.7 days, p = .0051), and more days in which
pain made it hard to do routine activities (adjusted mean
change = 1.2 days, p = .0045).
Among women aged 75–84, HRT discontinuers reported
more days at follow-up in which their physical health was
not good (adjusted mean change = 1.6 days, p = .0088).
No other significant differences in HRQOL between HRT
continuers and discontinuers were found in this age
group.BMC Women's Health 2005, 5:7 http://www.biomedcentral.com/1472-6874/5/7
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Table 2: Determinants of HRT discontinuation: results of propensity analysis
Multivariate Logistic Regression Results*
Variable HRT
Continuers
(N = 1342)
HRT
Discontinuers
(N = 1015)
Parameter 
Estimate (β )
Std. Error 
of β
Adjusted 
Odds Ratio
95% CI for 
Odds Ratio
P-value
Age
Age in years (mean) 75.5 75.5 0.0081 0.0075 1.041 0.993–1.023 .2847
Race
White (%) † 96.7 95.6 -- -- 1.000 -- --
Black (%) 2.7 3.5 0.3536 0.2527 1.424 0.868–2.337 .1616
Other race (%) 0.6 1.0 0.2903 0.4992 1.337 0.503–3.556 .5609
Income
Annual income in thousands (mean) $13.805 $13.999 0.0537 0.0245 1.055 1.006–1.117 .0283
Marital status
Widowed, divorced, or never married (%) † 80.6 80.5 -- -- 1.000 -- --
Currently married (%) 19.4 19.5 -0.1327 0.1384 0.876 0.668–1.149 .3378
Education
12 or more years of education (%) 60.5 63.5 0.0937 0.0899 1.098 0.921–1.310 .2971
Residence type
Nursing or personal care facility (%) 1.6 1.0 -0.4390 0.4067 0.645 0.291–1.431 .2804
Urban/rural residence
Semi-rural or rural residence (%) 33.6 35.5 0.1526 0.0913 1.165 0.974–1.393 .0948
Alcohol use
Current alcohol user (%) 26.5 24.4 -0.1335 0.1008 0.875 0.995–1.022 .1854
Smoking history
Past or present smoker (%) 34.7 33.0 -0.0573 0.0924 0.944 0.788–1.132 .5352
Type of HRT used at baseline
Unopposed estrogen (%) † 89.5 74.2 -- -- 1.000 -- --
Combination estrogen/progestin (%) 10.5 25.8 1.1100 .1171 3.034 2.412–3.817 .0001
Baseline non-HRT prescription drug use
Any cardiovascular drug use (%) 78.8 79.9 0.2265 0.1141 1.254 1.003–1.568 .0471
Any osteoporosis treatment (%) 12.2 15.4 0.3100 0.1270 1.363 1.063–1.749 .0146
Total number of non-HRT drug classes (mean) 6.3 5.9 -0.0507 0.0165 0.951 0.920–0.982 .0021
Baseline HRQOL
Days that physical health was not good (mean) 6.3 6.3 0.0086 0.0069 1.009 0.995–1.022 .2174
Days that mental health was not good (mean) 3.3 3.0 -0.0042 0.0067 0.996 0.983–1.009 .5323
Healthy days (mean) ‡ 21.9 22.3 -- -- -- -- --
Days that health interfered (mean) 4.2 3.8 -0.0113 0.0077 0.989 0.974–1.004 .1432
Days that pain made it hard (mean) 6.3 6.4 0.0060 0.0064 1.006 0.993–1.019 .3514
* All parameter estimates are adjusted for two-way interaction terms involving age, income, marital status, alcohol use, smoking history, 
prescription drug use, and baseline HRQOL.
† Reference group
‡ Because the healthy days variable is a composite of the physical and mental days measures, it was omitted from the logistic regression.BMC Women's Health 2005, 5:7 http://www.biomedcentral.com/1472-6874/5/7
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In contrast to the apparent declines in HRQOL experi-
enced by younger women who discontinued HRT, women
aged 85 or older who discontinued HRT appeared to expe-
rience improvements in several HRQOL measures, while
older continuers experienced declines. As shown in Table
2 and Figures 1 through 5, HRT discontinuers in this age
group showed fewer days in which physical health was
not good at follow-up, compared to baseline, while HRT
continuers reported more "not good" physical days rela-
tive to baseline (adjusted mean changes for HRT continu-
Table 3: Results of ANCOVA to compare HRQOL change in HRT continuers and discontinuers, by age group
Raw Mean Scores
Continuers Discontinuers
Follow-up Measure Age 
Group
N Time 1 Time 2 Time 1 Time 2 Source of Variation Sum of 
Squares
DF F Value Significance 
of F
Number of days that 
physical health was not 
good
65–74 810 5.19 5.27 5.17 6.31 Baseline physical days 19431.83 1 286.97 <.0001
HRT group 218.26 1 3.22 .0730
75–84 820 6.27 6.24 6.18 7.77 Baseline physical days 25852.59 1 348.90 <.0001
HRT group 510.31 1 6.89 .0088
85+ 140 7.49 9.81 7.86 5.39 Baseline physical days 4130.90 1 50.34 <.0001
HRT group 759.71 1 9.26 .0028
Number of days that 
mental health was not 
good
65–74 810 2.53 2.67 2.75 3.78 Baseline mental days 12963.01 1 309.92 <.0001
HRT group 190.93 1 4.56 .0329
75–84 820 2.49 3.67 2.52 3.12 Baseline mental days 11864.39 1 256.49 <.0001
HRT group 67.51 1 1.46 .2274
85+ 140 2.93 5.15 2.17 1.99 Baseline mental days 1402.63 1 23.85 <.0001
HRT group 287.32 1 4.88 .0287
"Healthy days" 
composite
65–74 810 23.43 23.30 23.43 21.97 Baseline healthy days 28043.55 1 340.82 <.0001
HRT group 348.18 1 4.23 .0400
75–84 820 22.41 21.81 22.59 20.89 Baseline healthy days 34431.84 1 388.18 <.0001
HRT group 222.31 1 2.51 .1138
85+ 140 20.81 17.96 20.44 22.82 Baseline healthy days 5494.08 1 53.96 <.0001
HRT group 914.52 1 8.98 .0032
Number of days that 
physical or mental 
health interfered with 
activities
65–74 810 3.22 3.40 3.17 4.89 Baseline interference days 14886.08 1 256.99 <.0001
HRT group 455.88 1 7.87 .0051
75–84 820 3.63 4.70 3.77 5.20 Baseline interference days 19210.32 1 303.58 <.0001
HRT group 35.08 1 0.55 .4568
85+ 140 5.15 7.46 4.36 5.14 Baseline interference days 4440.59 1 54.06 <.0001
HRT group 121.65 1 1.48 .2257
Number of days that 
pain interfered with 
activities
65–74 810 5.71 5.29 5.67 6.91 Baseline pain days 29680.32 1 446.86 <.0001
HRT group 539.67 1 8.13 .0045
75–84 820 5.80 7.02 5.88 7.65 Baseline pain days 33113.98 1 425.40 <.0001
HRT group 67.38 1 0.87 .3525
85+ 140 7.54 8.46 8.44 6.74 Baseline pain days 4637.67 1 53.90 <.0001
HRT group 169.95 1 1.98 .1621BMC Women's Health 2005, 5:7 http://www.biomedcentral.com/1472-6874/5/7
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ers and discontinuers were 2.2 and -2.4, respectively; p =
.0028). HRT continuers aged 85 or older also reported an
increase in days that mental health was not good, while
discontinuers experienced a slight decline (2.4 vs. -0.4, p
= .0287). For the composite healthy days measure, HRT
continuers experienced a mean decline of 2.8 days healthy
days, while discontinuers exhibited a mean increase of 2.3
healthy days (p = .0032). In this oldest age group, HRT
continuers and discontinuers did not differ significantly
in the number of days at follow-up that health interfered
with activities or that pain made it hard to do activities.
Discussion
The goal of this study was to assess changes in health-
related quality of life associated with discontinuation of
HRT in a sample of elderly women. To our knowledge, no
studies to date have specifically examined the impact of
HRT discontinuation on quality of life. Given the large
number of women who have either discontinued or will
discontinue HRT, it is important to understand the associ-
ations between HRT cessation and HRQOL. The results of
this study suggest that HRT discontinuation is associated
with changes in HRQOL, but the direction and magnitude
of these changes vary according to age. While HRT
Mean number of days that physical health was not good, by study occasion, age group, and HRT status Figure 1
Mean number of days that physical health was not good, by study occasion, age group, and HRT status. Raw 
means by study occasion are presented for each age group (65–74, 75–84, and 85+) and HRT continuation group (continuers 
vs. non-continuers). For each age group, the statistical significance of the HRT continuation group difference in HRQOL change 
(from ANCOVA analyses; see Table 3) is also shown.
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discontinuation was associated with apparent HRQOL
declines among younger women in this study, women
aged 85 or older appeared to experience improvements in
HRQOL following HRT cessation.
The HRT discontinuation rate of 43% observed in this
study is consistent with other recent reports. A recent
study of U.S. national HRT prescribing rates found that
overall HRT use declined by 38% between 2002 and
2003, with higher declines observed for combination
therapy than for unopposed estrogen therapy [7]. The
majority of HRT users in the present study used unop-
posed estrogen, warranted only for women without uteri.
The high observed rate of unopposed estrogen use in this
sample is supported by a 2000 PACE survey which found
that, while 40% of all female respondents reported a prior
hysterectomy, 75% of current HRT users reported having
had a hysterectomy. These results suggest that
hysterectomy history may play an important role in pre-
scribers' decisions to initiate or continue HRT in elderly
women.
Depending on the specific measure examined, HRT dis-
continuers aged 65–74 averaged an increase of one to two
days per month in which HRQOL was suboptimal. The
results described here do not explain what factors may
have mediated this decline. Possibilities include acute
vasomotor symptoms, such as flushing, which have been
Mean number of days that mental health was not good, by study occasion, age group, and HRT status Figure 2
Mean number of days that mental health was not good, by study occasion, age group, and HRT status. Raw 
means by study occasion are presented for each age group (65–74, 75–84, and 85+) and HRT continuation group (continuers 
vs. non-continuers). For each age group, the statistical significance of the HRT continuation group difference in HRQOL change 
(from ANCOVA analyses; see Table 3) is also shown.
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shown in prior studies to be important mediators of
depression in menopausal women [31]. Alternatively,
there may be more complex physiological effects of HRT
discontinuation that affect mood, pain perception, or
other aspects of perceived health.
The BRFSS HRQOL measures employed in this study have
been previously shown to predict morbidity and mortality
in the PACE population [32]. Based on the significant
associations of these measures with HRT discontinuation
it is plausible that HRT cessation may affect risk for some
adverse outcomes, although data needed to address this
question are not yet available. Recent work suggests that
HRT discontinuation is associated with reduced bone
density and increased fracture risk [33,34]. On the other
hand, given the risks for breast cancer and cardiovascular
disease that appear to be attributable to HRT,
discontinuation may result in reduced risk for these out-
comes. Clearly, more research is needed to explore the
complex relationships among age, HRT cessation,
HRQOL, and specific health outcomes.
A strength of this study is that it takes advantage of a nat-
ural experiment afforded by the availability of repeated
survey data, which were collected during the general time
period in which large numbers of women discontinued
Mean number of "healthy days", by study occasion, age group, and HRT status Figure 3
Mean number of "healthy days", by study occasion, age group, and HRT status. Raw means by study occasion are 
presented for each age group (65–74, 75–84, and 85+) and HRT continuation group (continuers vs. non-continuers). For each 
age group, the statistical significance of the HRT continuation group difference in HRQOL change (from ANCOVA analyses; 
see Table 3) is also shown.
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HRT. However, an important caveat regarding our find-
ings is that our study design compared women who had
either continued or discontinued HRT as of their follow-
up survey date, but did not model the time course of
HRQOL change following HRT discontinuation. There-
fore, although the time interval between the baseline and
follow-up surveys was approximately one year for all
study subjects, the interval between HRT cessation and the
follow-up survey response date could range from approx-
imately one month to approximately one year. We con-
ducted additional analyses to examine the impact of time
since HRT cessation on HRQOL among discontinuers.
Those analyses found no gradient in HRQOL change asso-
ciated with the time elapsed since discontinuation.
However, sample size considerations limited our
statistical power to detect such differences. Further
research is needed to model the time course of HRT
discontinuation and its impact on HRQOL, and to
examine whether short-term changes in HRQOL follow-
ing cessation persist over time.
Due to the greater age and burden of illness present in the
PACE population, the results of this study are limited in
their generalizability to other populations, including
Mean number of days that health interfered with activities, by study occasion, age group, and HRT status Figure 4
Mean number of days that health interfered with activities, by study occasion, age group, and HRT status. Raw 
means by study occasion are presented for each age group (65–74, 75–84, and 85+) and HRT continuation group (continuers 
vs. non-continuers). For each age group, the statistical significance of the HRT continuation group difference in HRQOL change 
(from ANCOVA analyses; see Table 3) is also shown.
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younger women. These unique features of PACE, how-
ever, provide a valuable opportunity to examine the
impact of HRT use and HRT discontinuation on elderly
women. Most studies of HRT use have focused on women
in the immediate postmenopausal years rather than eld-
erly women. The present study, therefore, provides new
information about the impact of HRT use and cessation
on elderly women. The mean age of HRT users in this
study was 75.5 years, and HRT users' ages at baseline
ranged from 65 to 102. Although the large number of very
old HRT users may be somewhat surprising, it is consist-
ent with unpublished research indicating that 28% of
PACE HRT users in 2000 were aged 80 or older. The same
study found that, among current HRT users, the mean self-
reported duration of use was 17.8 years, and 25% of cur-
rent users reported that they had used HRT for 28 years or
longer. These results highlight the need for awareness
regarding the prevalence of very long-term HRT use by
elderly women for whom menopause may have occurred
several decades in the past.
A number of statistical limitations that could have a bear-
ing on the results reported here should be noted. In this
observational study, we sought to reduce selection bias
through the use of propensity scores and by matching
continuers with discontinuers on the basis of multiple fac-
tors. Comparison of the baseline HRQOL means for con-
tinuers and discontinuers suggested that the groups were
Mean number of days that pain made activities difficult, by study occasion, age group, and HRT status Figure 5
Mean number of days that pain made activities difficult, by study occasion, age group, and HRT status. Raw 
means by study occasion are presented for each age group (65–74, 75–84, and 85+) and HRT continuation group (continuers 
vs. non-continuers). For each age group, the statistical significance of the HRT continuation group difference in HRQOL change 
(from ANCOVA analyses; see Table 3) is also shown.
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well balanced in terms of baseline HRQOL. One limita-
tion of this study, however, is that despite the statistical
procedures employed to reduce bias, it is still possible that
women who discontinued HRT differed in unmeasured
ways from women who continued HRT. Conversely,
because we matched on multiple variables as well as the
propensity score, another statistical limitation relates to
possible overmatching, as discussed by Rothman and
Greenland [35]. To the extent that matching may have
been performed on variables related to HRT use but not to
HRQOL, statistical efficiency may have been reduced. Of
greater concern is the possibility that some matching
variables may have been directly related to HRQOL
change, which could lead to additional bias [35].
Another limitation of this study is one that is inherent in
any study relying on pharmacy claims data – HRT usage
was inferred from prescription claim records. It is not
known to what extent women who filled HRT prescrip-
tions actually took the medication, or if the data recorded
by the pharmacy at the point of sale accurately described
patients' dosing instructions from their physicians. It is
also possible that some women who did not fill prescrip-
tions for HRT had access to the medication through other
sources, such as samples received from physicians.
Another important consideration relates to potential age-
related measurement errors, such as recall bias, which
may have affected women's perceptions of their HRQOL
over the last 30 days. Age differences in women's expecta-
tions regarding the anticipated effects of HRT discontinu-
ation could also be a factor. These limitations underscore
the need for further studies to explicate the determinants
and outcomes of HRT discontinuation.
Despite these limitations, the pattern of results observed
in this study is an important reminder that even popula-
tions defined on the basis of age – such as PACE, for
which the minimum eligible age is 65 – may include a
broad range of ages with associated heterogeneity. Our
results suggest that the response to HRT discontinuation
among women aged 85 or older may be quite different
from that of women in their 60's or 70's. The etiology of
the age differences seen in this study is not known, and
may reflect cohort effects, including the age-related meas-
urement issues discussed above, or alternatively, the
results may reflect physiological differences related to
aging. Other recent work suggests that there are important
age differences in the effects of estrogen on various physi-
ological systems. For example, Brownley and her col-
leagues have recently reported differential associations
between HRT and blood pressure according to the time
elapsed since menopause [36]. There is also growing evi-
dence from animal studies that the effects of estrogen
replacement on neurological function may be attenuated
with increasing age [37]. As discussed by Savonenko and
Markowska [37], such findings suggest that aging proc-
esses may modulate the mechanisms by which estrogen
exerts physiological effects.
Regardless of the mechanisms that may explain the pat-
tern of HRQOL changes reported in this study, the
declines observed among younger HRT discontinuers
emphasize the need for communication between clini-
cians and patients throughout the discontinuation proc-
ess. Based on current evidence obtained from clinical
trials, HRT increases risk for breast cancer, stroke, and
other adverse health outcomes. On that basis, HRT dis-
continuation is rational and may provide important
health benefits. Nevertheless, short-term changes in
HRQOL may occur following HRT cessation, and strate-
gies to optimize the discontinuation process are needed.
For example, current recommendations for HRT discon-
tinuation advocate a gradual cessation in which dosing is
tapered over a three to six month period [38,39]. Ideally,
future research efforts will evaluate differences in HRQOL
change according to the intensity and duration of the ces-
sation process.
Conclusions
This is the first study to present information about the
impact of HRT discontinuation on HRQOL in elderly
women. The results of this study suggest that there are sig-
nificant age differences in response to HRT discontinua-
tion. We believe that the present study furthers knowledge
regarding older women's health in several important
ways. First, it provides new information about potential
declines in quality of life that women in their 60's and
70's may experience shortly after discontinuation of HRT.
Awareness of these potential changes may help clinicians
and patients to prepare for the discontinuation experi-
ence. These results have implications for clinical practice,
suggesting that more clinical and social support may be
needed for older women discontinuing HRT. These find-
ings also highlight the importance of communication
between health care providers and patients throughout
the discontinuation process. Secondly, the results of this
study suggest that many women aged 85 or older, includ-
ing long-term users of HRT, may be able to discontinue
HRT with little or no negative impact on quality of life. In
fact, some women in this age group may experience
improvements in quality of life upon HRT cessation,
although the mechanisms involved in the observed
improvements are not yet understood.
Finally, this study also has implications for health policy
in that it illustrates the value of health monitoring and
surveillance as a component of health program adminis-
tration. Health-related quality of life is an important fac-
tor that should be considered when making clinical
decisions and developing health policies. By adding anBMC Women's Health 2005, 5:7 http://www.biomedcentral.com/1472-6874/5/7
Page 14 of 15
(page number not for citation purposes)
optional survey to the application process, the PACE Pro-
gram has demonstrated a commitment to understanding
the health status and needs of its older patient population.
The use of survey measures such as those described in this
study provide a useful framework for the evaluation of
clinical program initiatives, and also provide a valuable
resource for addressing relevant research questions. We
hope that the work described here may encourage
administrators of other programs to consider adopting
similar health surveillance strategies.
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